Status:
COMPLETED
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
Lead Sponsor:
AstraZeneca
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
Eligibility Criteria
Inclusion
- Patient has a documented clinical diagnosis of Major Depressive Disorder.
- Be able to understand and comply with the requirements of the study.
- Able to understand and provide written informed consent
Exclusion
- Patients (female) must not be pregnant or lactating
- Current or past diagnosis of stroke or transient ischemic attack (TIA).
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00320268
Start Date
April 1 2006
End Date
May 1 2007
Last Update
March 25 2009
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Little Rock, Arkansas, United States
2
Research Site
Newport Beach, California, United States
3
Research Site
Northridge, California, United States
4
Research Site
Oceanside, California, United States